Pharmaceuticals

Camzyos Demonstrates Efficacy and Safety in Treating Symptomatic Obstructive Hypertrophic Cardiomyopathy

bexib
By bexib 0 Min Read

Results from the Phase III EXPLORER-LTE trial found that Camzyos maintained efficacy in treating symptomatic obstructive hypertrophic cardiomyopathy after 3.5 years of treatment.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article Who will be tomorrow’s world’s richest people? We interviewed teenagers attending the world’s most expensive schools to find out
Next Article Internal and External Page Linking Tips
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

A look inside: Allies developing a multicloud hybrid strategy
Banking
2024 Holiday Shipping Deadline for the United States
International Shipping
Ecommerce taxes – How to stay ahead of the sales tax maze
Retail & E-commerce
Finastra breach: 3 security points
Banking